JP Morgan Initiates Coverage On Relay Therapeutics with Overweight Rating, Announces Price Target of $28

Benzinga Newsdesk www.benzinga.com Neutral 71.6%

Neg 0% Neu 71.6% Pos 0%

JP Morgan analyst Priyanka Grover initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Overweight rating and announces Price Target of $28.